ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Post-Hoc Study Analysis Examines Early Intervention with Edaravone for ALS Survival
March 25, 2021Mitsubishi Tanabe Pharma America announced a post-hoc analysis of its Phase 3 edaravone study reviewing the results of intravenous (IV) edaravone treatment on disease progression milestones and events among people with amyotrophic lateral sclerosis (ALS). -
MTPA Announces Initiation of Open-Label Extension Study of Oral Edaravone in ALS
January 08, 2021Mitsubishi Tanabe Pharma America (MTPA) announced the initiation of a long-term safety extension study (MT-1186-A03) to the ongoing Phase 3 trial evaluating an investigational oral formulation of edaravone in patients with amyotrophic lateral sclerosis. -
MT Pharma America announces corporate name change
August 16, 2017MT Pharma America, Inc. has announced the change of its corporate name to Mitsubishi Tanabe Pharma America, Inc. (MTPA), effective immediately.
Pharma Sources Insight January 2025
